BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//PitchBoulder - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PitchBoulder
X-ORIGINAL-URL:https://pitchboulder.co
X-WR-CALDESC:Events for PitchBoulder
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20260308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20261101T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20270314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20271107T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20260318T083000
DTEND;TZID=America/Chicago:20260318T103000
DTSTAMP:20260430T042134
CREATED:20260223T165102Z
LAST-MODIFIED:20260304T214313Z
UID:7467-1773822600-1773829800@pitchboulder.co
SUMMARY:Presenting: OncoPatch\, Inc. – Non-Invasive Skin Cancer Treatment
DESCRIPTION:OncoPatch\, Inc. (https://oncopatch.com) — Co-Founder David Westerly presenting\, is a medical device company developing a non-invasive radiotherapy patch for the treatment of non-melanoma skin cancer. \nNon-melanoma skin cancer incidence exceeds all other cancers combined\, with more than 5 million lesions treated annually in the U.S. Today\, most patients undergo surgery\, an invasive procedure that can result in pain\, scarring\, and recovery time. \nOncoPatch provides a non-surgical alternative using patches that contain the beta-emitting isotope yttrium-90\, delivering targeted radiotherapy directly to the lesion. The treatment can be completed in as little as one 30-minute session in a dermatologist’s office. The result is effective cancer treatment with reduced invasiveness and improved patient experience. \nOur target market is dermatologists and outpatient dermatology clinics in the U.S. who need effective\, in-office alternatives to surgical excision and are willing to pay for improved patient outcomes\, convenience\, and differentiated treatment offerings.\nOur competition is surgical excision\, Mohs surgery\, and topical chemotherapy treatments. Our competitive advantage is a single-session\, non-invasive radiotherapy solution that reduces procedural burden while maintaining clinical efficacy. \nThe total market size in 2024 is the U.S. non-melanoma skin cancer treatment market\, and the total market revenue in 2024 is $8B+. \nTop 3 challenges: \n\nSelling into dermatology practices and navigating adoption barriers\nOvercoming early-stage limitations in clinical data\nScaling a clinical service model to support device rollout and training\n\nOur PitchBoulder ask: We are currently raising a $2.5M seed round and are over 50% committed. We’d welcome conversations with interested investors and candid feedback on how to strengthen our pitch from an investor’s perspective — particularly around clinical validation\, regulatory strategy\, and go-to-market execution.
URL:https://pitchboulder.co/event/presenting-oncopatch-inc-non-invasive-skin-cancer-treatment/
LOCATION:Galvanize Boulder\, 1023 Walnut St.\, Boulder\, CO\, 80302\, US
ATTACH;FMTTYPE=image/jpeg:https://pitchboulder.co/wp-content/uploads/2026/02/7467_image_highres_532885665.jpeg
ORGANIZER;CN="PitchBoulder":MAILTO:PitchBoulder-announce@messages.meetup.com
END:VEVENT
END:VCALENDAR